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Breast-Feeding in cystic fibrosis: an Italian, single centre follow-up 
survey 
C. Colonabo 1, V. Bennat o 1, O. Ronaalao 1,C. Fredella 1, D. GhislenF, M. GiovarminF, 
E. Riva 9, C. AgostonF 
Department of Pediatrics, CF Center arm San Paolo Hospital, University of Mila~ 
Milan, Italy 
Beneficial effects of breas~feeding (BF) have been described ha inborn errors of 
metabolism and recently ha CF. 
AIMS. To investigate height achievement, rate of infections ha the first 3 yrs of age, 
incidence of Pseudomonas (Pa) infection and lung function ha CF patients according 
to early type of feeding and CFFR genotype. 
METHODS. We studied 105 CF children (52 males, mean (+SD) age 8+ 4 yrs, 
severe/mild genotype 72/33). During a follow up visit, dietary and anamnestic data 
were collected, and anflaropometric (transformed into z scores) and pulmonary 
function parameters were assessed. Statistical analysis included chi square, 
parametric and non parametric tests, as appropriate (SPSS 11.5 for Windows). 
RESULTS. Among BF children, mean (+ SD) duration of BF was 5+4 mos (range 
1 to 30). BF was more prevalent in patients with mild (26/33) compared to severe 
(42t72) genotype (P 0.04). Considering all the 105 subjects, a trend of association 
was found between BF duration mad height z score attainment 0P~).07), whi le  BF 
> 6 mos (n 15) vs no BF (n 36) was associated to a reduction in episodes of 
infections during the first 3 years of l ife (5+4 vs 9+6 episodes, P~).04). The same 
trends were present in patients with severe and mild genotype. Rate of Pa infection 
and age at first acquisition were related to CF genotype mad not BF. BF was 
associated with better lung function only in patients with mild genotype, with clear 
trend of correlations (r 0.38, P 0.07, for FEV1, and r 0.46, P 0.02, for FVC, 
respectively). 
CONCLUSIONS. BF, particularly i f  protracted, is associated to better growth, 
health and functional outcomes ha CF and seems to benefit more those with mild 
genotypes. 
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Reproducibility of dietary intake assessment in children with CF 
versus normal controls 
M. Pr oesmmas, L. Vanharen, K. De  Boeck 
CF centre, University Hospital Gasthuisberg, Leuve~ Belgium 
Aim:  Evaluation of the reproducibility of the prospective 3 day weighed food record 
in chi ldren with cystic fibrosis (CF) and healthy control (HC). 
Methods:  Parents of 24 children with CF aged 8 12 years (mean 10 years; 15 
female,) were asked to perform 3 day weighes food records at home (twice with one 
month interval) ha a period of stable disease. For each food record total dai ly caloric 
intake (Cal), daily intake of fat (g/day and energy%), dai ly protein, carbohydrate, 
f ibre and calcium intake were calculated. The same was done for 25 HC in the same 
age category (mean age 10 years; 10 female). Differences (t test) between the first 
and second dietary calculations and differences between CF and HC were analysed. 
Results: Mean daily caloric intake was 2220 for CF versus 1926 for HC 
(p~3.0056). No significant difference was found for CF patients and HC between 
the 2 assessments. Mean daily fat intake was 88 gram fat /day for CF and 74 gram 
for HC (I 9 0.008) which was 36 energy% for CF versus 35 % for controls. For CF 
patients dai ly fat intake did not significantly differ between the 2 assessments (p
0.34) with a median difference of 2g and a correlation coefficient of 0.58 between 
the 2 measurements. Similar results were obtained for HC 
Mean dietary fibre intake was the same ha CF and HC: 14gram/day. Dai ly calcium 
intake was 826 mg for CF vs 752 mg for HC. Median differences between the 2 
calculations were not significant in the CF and HC group. 
Conclusion Assessment of dai ly dietary intake using the 3 day weighed food record 
is sufficiently reproducible and is therefore a rel iable method to investigate daily 
feeding in CF patients and healthy controls. In our CF children dietary needs are not 
always reached. 
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Accumulation of neutr ophils releasing proteolytic enzymes and free radicals induce 
progressive lung tissue destruction in CF. Among several hfflammatory mediators 
implicated in this process, leukotriene B 4 (LTB4) product of arachidonic (AA; 
20:4n 6) omega 6 polytmsaturated fatty acid (PUFA) plays an important role. 
Various anti inflammatory strategies including dietary supplementation f omega 3
PUFA, known to favor the synthesis of less active leukotriene B 5 (LTBs), have been 
investigated. To further explore this nutritional approach, biological effects of an 
omega 3 PUFA oral supplementation (n 3 OS) were measured in 17 CF patients ha 
a prospective, randomized, double blind, crossover study. CF patients (mean age: 
18 + 9 years, FEVI: 66 + 29 %) received a dietary supplementation enriched, or not, 
ha omega 3 PUFA during a 2 x 6 months period. A modification in neutrophil 
membrane PUFA composition was observed under n 3 OS with an increase in EPA 
(20:5n 3) PUFA (from 0.66 ± 0.56 to 1.60 ± 0.61 ~tmol %, P< 0.01). The LTB j LTB  5 
ratio was decreased (from 72 + 27 to 24 + 7, P< 0.C~31), in CF patients taking n 3 
OS. However, n 3 OS supplementation did neither affect the internalization f both 
IL 8 receptors fol lowing IL 8 exposure, nor IL  8 induced neutrophil chemotaxis. 
Our results show that n 3 PUFA are absorbed and incorporated in neutrophil 
membrmae. The consecutive decrease ha LTBjLTB 5 ratio suggests that, ha these 
conditions, neutr ophils may produce less toxic mediators from the AA pathway. The 
potential cl inical benefit for CF patients still needs to be assessed with further 
studies of longer duration and including more patients. 
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Gastrostomy tube removal in CF - is it wise? 
H. Elyashar Baron, E. Kerem, S. Ar moni, M. Wilschanski 
CF Center; Hadassah University Hospital, Mt. Scopus, Jerusalem, Israel 
Malnutrit ion is a common problem in cystic fibrosis (CF) patients, despite 
pancreatic enzyme supplementation and increased caloric intake. When oral 
supplementation fails, additional overnight gastrostomy tube feeding (OT) is a 
successful therapeutic option. Unti l  recently, OT ha CF patients were not removed. 
We present 2 cases where successful removal cectared. Two CF patients were 
treated with overnight gastrostomy feeding for several years. Case 1. GT was 
insetted into a patient at the age of 12 months after 6 months of night feeding by 
nasogastric tube. Her weight percentile improved from under the 3 ~d percentile to 
the 10 t~ percentile within 2 years. At  the age of 8 years she reduced the night feeding 
and increased oral intake. She maintained her BMI  (25 m percentile) for over a year 
and at the age of 9 years the GT was removed at her request. One year later, she 
continues to eat wel l  and gain weight whi le  maintaining her BMI. Case 2. This 
patient required sporadic supplemental night feeding by nasogastric tube from the 
age of 6 months. At  the age of 5.5 years GT was insetted, and significant weight 
gain c¢curred. She demonstrated severe food refusal but maintained her weight on 
the 10 25 percentile. At  the age of 11.5 years sbe stopped using the GT, and after 6 
months of continuing to tbrive the GT was removed at her request. 
Gas~rostomy use is of utmost importance in CF when caloric supplementation is 
indicated but, even ha CF, it may be required only temporarily, ha these two cases, 
females who were fed by nasogastric tube and then by GT, were able to continue 
tbriving without supplemental nutrition. As of now, the decision to remove the GT 
has not been regretted. Longer term and larger studies wi l l  be required to confirm 
this practice. 
